Navigation Links
Chiltern Wins Top Prize
Date:3/5/2008

LONDON, March 5 /PRNewswire/ -- Chiltern, a leading global research organization, is proud to announce that it won 4 'Pharmas' at the PharmaTimes Clinical Researcher of the Year ceremony, including the coveted Clinical Department of the Year.

Chiltern received the following awards:

Gold: Clinical Department of the Year - Chiltern International

Gold: Anne Tebbatt in the Project Manager category

Gold: Kara Tanabe in Clinical Research Associate category

Silver: Donna Sexton in Clinical Research Associate category

"We are delighted that these four awards, at such a high profile and well recognized industry event, recognize Chiltern's strengths in both the Global Clinical Development and the Resourcing Solutions models," commented Linda Christmas, Executive Vice President Resourcing Solutions, who accepted the Clinical Department of the Year award for Chiltern. This award recognizes the best overall performance by a company combining all categories and is an outstanding achievement.

The PharmaTimes Clinical Researcher of the Year competition is designed to recognize and reward excellence in pharmaceutical clinical development across Europe. Unlike other awards, these measure individual competence in an exposed environment where finalists go through several preliminary rounds culminating in presentations to seasoned and senior industry managers.

In total Chiltern had four finalists in the individual categories all of whom started with Chiltern as trainees and most of whom have worked both in house and on assignments in sponsors' offices. This lays testament to the excellent training and opportunities offered by the company to its staff, both within the CRO and Resourcing Solutions service offerings.

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience of running and staffing international Phase I to Phase IV clinical trials a
'/>"/>

SOURCE Chiltern
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Marco Romano, MD Joins Chiltern as Medical Director, Europe
2. Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
3. Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc.
4. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
5. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
6. Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
7. 2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki
8. Prize for Cutting-Edge Laser Innovations
9. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
10. Two more American Cancer Society researchers win Nobel Prize
11. Nobel Honors 3 Former March of Dimes Prize Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... Today the Centers for Disease Control and Prevention (CDC) ... the week was designed to highlight the importance of ... of taking additional steps to keep you and your ... of December, January and beyond. ,, "It,s easy to ... topic of both seasonal and swine flu," said Dr. ...
(Date:12/6/2009)... BROOK, Ill., Dec. 7 The University ... (AMC) members for their achievements in UHC,s Supply ... organizations are noted for modeling best practices in ... http://www.newscom.com/cgi-bin/prnh/20091207/CG21708 ) ,, The winners were determined ... that includes contract portfolio participation and use of ...
(Date:12/6/2009)... future treatments targeting growth factor, researchers say , , ... breast cancer cells from the main tumor to other ... factor known as TGFb, which may prove a promising ... British researchers say. , Previous studies have shown that ... and movement. In this new study, a team from ...
(Date:12/6/2009)... Dec. 6 Blood clotting, or coagulation, ... when a blood vessel is injured. Sometimes, however, ... an obvious injury or do not dissolve naturally, ... today at the 51st Annual Meeting of the ... of using the anticoagulants aspirin and heparin with ...
(Date:12/5/2009)... shown in a phase 1/2 clinical trial that ... of patients newly diagnosed with multiple myeloma, a cancer ... from Dana-Farber Cancer Institute. , Partial responses or better ... with the drug combination in the multi-center study, with ... in the phase 2 population, reports Paul G. Richardson, ...
Breaking Medicine News(10 mins):Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 2Health News:As CDC Kicks Off National Influenza Vaccination Week, It Is More Important than Ever to Take Preventative Measures Against Cold & Flu 3Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Breast Cancer's Spread Now Better Understood 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2
... Provide General Information about Potential Health ConcernsNEWTON, Mass., May ... in the reinvention of how people obtain legal services, ... general information about the potential health hazards of excessive ... consumer product used by an estimated 35 million Americans ...
... colleague Tom Daulton to provide strategic leadership as ... PRAIRIE, Wis., May 5 Devicor Medical Products, ... Executive Vice President, Corporate Development & Strategy. Salkin,s ... the Royal Bank of Scotland plc is highlighted ...
... BERLIN, May 5 Anatomist, Dr. Gunther von Hagens, ... set out three years ago to present the human ... his "HUMAN SAGA" project this week.(Photo: http://www.newscom.com/cgi-bin/prnh/20090505/CG11117 ... hoped to traverse the anatomical landscape left uncharted by ...
... According to a new study led by researchers at ... several factors that contribute to children missing immunization visits. ... presentation at 8:30 a.m. ET on Tuesday, May 5, ... here. , "We know that approximately 20 percent ...
... Will Host ,Day of Dialogue, Online Town Hall Meeting on ... America,s healthcare and long-term services need to undergo a ... seniors and people with disabilities, according to a report released ... report, which will be supported by a nationwide "Day of ...
... Health Care Management WASHINGTON, May 5 ... education organization, announced today that Christine G. Leyden, Senior ... Accreditation Officer for URAC has been recognized as a ... Point magazine. Ms. Leyden will be featured in ...
Other Medicine News:Health News:Sokolove Law Launches Denture Cream Consumer Hotline 2Health News:Jonathan Salkin Named Executive Vice President of Devicor Medical Products 2Health News:Dr. Gunther von Hagens 'HUMAN SAGA' Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life. 2Health News:Why parents miss their children's immunization visits 2Health News:Why parents miss their children's immunization visits 3Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 2Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 3Health News:Case in Point Magazine Names URAC Senior Vice President Leader in Health Care Accreditation 2Health News:Case in Point Magazine Names URAC Senior Vice President Leader in Health Care Accreditation 3
(Date:12/4/2009)... Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: ... testing of a novel integrated light source architecture for ... design raises the bar on imaging speed and overcomes ... light sources. This approach to optical engines builds ...
(Date:12/4/2009)... N.Y., Dec. 4 Bayer Diabetes Care today announced the ... Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the ... the country. The grand prize is an in-person meeting today ... 1 diabetes like Nick, are: Caleb, age 6, from Danbury, ...
(Date:12/4/2009)... AstraZeneca (NYSE: AZN ) today announced that ... once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as ... Depressive Disorder (MDD). SEROQUEL XR is the only medication ... both major depressive disorder as adjunctive therapy and acute ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leg Clots May Not Travel to Lungs 59796 1Leg Clots May Not Travel to Lungs 59796 2Leg Clots May Not Travel to Lungs 59796 3Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 1Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 2Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 3Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 4Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 5Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement 5585 6Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals 5582 1Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals 5582 2Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals 5582 3
... 10 Endo Pharmaceuticals (Nasdaq: ENDP ) ... agreements to develop novel treatments for pain and to ... with Harvard University , is based upon a ... Harvard Medical School,s Richard J. Kitz Professor of Anaesthesia ...
... new study published today claiming that multivitamin use by ... mortality fails to take into account important dietary factors ... are regulated by the U.S. Food and Drug Administration ... the February 9 issue of Archives of Internal ...
Other Medicine Technology:Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 2Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments 3Evidence Lacking in Multivitamin Study of Women's Risk of Cancer, Heart Disease or Death, Says Natural Products Association 2
... GE Healthcares new Vivid i ... cardiovascular ultrasound system to provide high-performance, full-featured ... Vivid i addresses one ... access to complete, real-time diagnostic information. ...
The Bio-Quant TROPONIN I test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of cardiac,troponin I (cTnI) in human serum specimens as an aid i...
This advanced digital monitor detects the appearance of an irregular heartbeat during measurement and gives a warning signal with your reading. An irregular heartbeat may cause or indicate cardiovasc...
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
Medicine Products: